Authors
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédéric Selle, Mansoor R Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh KB Parmar, Amit M Oza
Publication date
2011/12/29
Journal
New England Journal of Medicine
Volume
365
Issue
26
Pages
2484-2496
Publisher
Massachusetts Medical Society
Description
Background
Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.
Methods
We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survival.
Results
A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a …
Total citations
Scholar articles
TJ Perren, AM Swart, J Pfisterer, JA Ledermann… - New England Journal of Medicine, 2011